This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

The present application relates to K-Ras mutations, to polynucleotides encoding mutant K-Ras polypeptides, and to methods of identifying small molecule antagonists using K-Ras mutations. The present application also relates to K-Ras small molecule antagonists and use thereof in the treatment of tumors.

The present application relates to K-Ras mutations, to polynucleotides encoding mutant K-Ras polypeptides, and to methods of identifying small molecule antagonists using K-Ras mutations. The present application also relates to K-Ras small molecule antagonists and use thereof in the treatment of tumors.

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.

Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.

Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2H,6H-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5-pyrimidine]-2,4,6(1H,3H)-trione, or a pharmaceutically acceptable salt thereof.

Disclosed are methods for treating various bacterial infections with (2R,4S,4aS)-11-fluoro-2,4-dimethyl-8-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1,2,4,4a-tetrahydro-2H,6H-spiro[1,4-oxazino[4,3-a][1,2]oxazolo[4,5-g]quinoline-5,5-pyrimidine]-2,4,6(1H,3H)-trione, or a pharmaceutically acceptable salt thereof.

This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.

This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.